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Summary
The most important prognostic factor in oral squamous cell carcinoma (OSCC) is the presence of metastases in  regional 
lymph nodes. Study group comprised of 107 patients with OSCC and control group comprised of 77 specimens of  unchanged 
oral mucosa. The purpose of this study was to determine the immunohistochemical expression of cathepsin D and nm23 
protein in OSCC and to compare it to the other clinical and histological features and to the occurrence of regional metasta-
ses, in order to assess their prognostic value. In contrast to normal epithelium a diff use expression of cathepsin D and nm23 
protein in OSCC has been found. By comparing the expression of cathepsin D and nm23 protein in tumor cells and in tumor 
stroma and the type of reaction to the pT, the degree of diff erentiation, mode of invasion and tumor stroma the following 
has been found: a signifi cant connection between nm23 protein in tumor cells with the degree of diff erentiation, nm23 pro-
tein with the characteristics of the tumor stroma and mode of invasion and cathepsin D with the degree of tumor diff eren-
tiation. The results of this research highlight the important role of tumor stroma in metastatic potential of OSCC. 
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POVEZANOST PROTEINA nm23 I KATEPSINA D SA KLINIČKIM I PATOLOŠKIM ZNAČAJKAMA 
ORALNOG KARCINOMA PLOČASTIH STANICA
Sažetak
Svrha ovog istraživanja bila je imunohistokemijski utvrditi izraženost proteina nm23 i katepsina D u oralnim ploča-
stim karcinomima, usporediti ju s patohistološkim nalazima, pojavom područnih presadnica i procijeniti njihovu vrijednost 
u prognozi bolesti. Ispitivano je 107 tkivnih uzoraka bolesne i 77 zdrave ustne sluznice. Uočena je pojačana difuzna izraže-
nost proteina nm23 i katepsina D u bolesnom tkivu. Usporedbom proteina nm23 i katepsina D u tumorskim stanicama i 
tumorskoj stromi, te tipa reakcije s pT, stupnjem diferencijacije, načinom invazije i izraženošću tumorske strome, nađena je 
znakovita povezanost izraženosti proteina nm23 u tumorskim stanicama sa stupnjem diferencijacije, proteina nm23s izraže-
nošću tumorske strome i načinom invazije, te katepsina D sa stupnjem diferencijacije tumora.Najvažniji prognostički poka-
zatelj u oralnim pločastim karcinomima su metastaze u područnim limfnim čvorovima. Rezultati istraživanja pokazuju 
važnost  tumorske strome za metastatski potencijal ostnog ustnog pločastog karcinoma. 
KLJUČNE RIJEČI: planocelularni karcinom, protein nm23, katepsin D
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INTRODUCTION
Cathepsins are proteolytic enzymes found 
and expressed in human tissues which can be di-
vided into three subgroups, depending on their 
specifi c proteolytic activity: cysteine protease ca-
thepsines (B,C,H,F,K,L,O,S,V,W), aspartic protease 
cathepsins (D, E) and serine protease cathepsins 
(G) (1, 2, 3). Main intracellular physiological func-
tions of cathepsin D are metabolic protein degra-
dation, activation of precursors of bioactive pro-
teins and processing of antigens, polypeptide hor-
mones and growth factors (1, 2, 3). It also plays an 
important role in regulation of programmed cell 
death. In the extracellular environment cathepsin 
D takes part in degradation of extracellular matrix 
and other processes unrelated to its catalytic activ-
ity, such as fi broblast, endothelial and epithelial 
cell growth induction, neovascularization, tissue 
remodeling and homeostasis (2, 4, 5).
Some of the cathepsin enzymes, particularly 
cathepsin D and cystein protease cathepsin B and 
L, are involved in tumor progression and metasta-
sis (6 - 8, 10, 11). It has been shown that in the ma-
jority of breast carcinoma tissue expression of ca-
thepsin D was 2 to 50 times more elevated than in 
the surrounding fi broblasts or normal glands. Ac-
cording to several clinical studies, the concentra-
tion of cathepsin D in the cytosol of breast cancer 
cells is an independent prognostic factor that cor-
relates with higher incidence of metastasis and 
shorter survival (2, 6, 9). It has been suggested that 
some of the cathepsin D increasingly produced by 
cancerous cells can enter the bloodstream, thus 
showing elevated concentration of procathepsin-
D in blood in patients with metastatic disease (2). 
Elevated levels of cathepsin D in patients with oral 
squamous cell carcinoma, oropharynx and hypo-
pharynx carcinoma were associated signifi cantly 
with the occurrence of regional metastases, re-
gardless of tumor stage and histological grade (10, 
11, 12, 13). Cathepsin D is mostly produced in car-
cinoma cells and stromal macrophages. Originally 
it was thought that the main role of proteases, 
such as cathepsin D, in metastasis, is facilitating 
the invasion of tumor cells by degrading extracel-
lular matrix and components of the basal mem-
brane (7, 5). Later on, it was experimentally con-
fi rmed that cathepsin D induces metastatic activi-
ty by inducing cell proliferation, more than it 
increases the invasive potential of the tumor, al-
though the mechanism hasn’t been completely 
elucidated (2).
Discovery of tumor suppressor genes’ loss of 
function as a key element in oncogenesis took fur-
ther to the assumption that functional losses of 
other genetic products can, in a similar fashion, al-
low metastatic spreading. So far around 11 metas-
tasis suppressor genes were discovered, all of 
which have in common suppression of metastasis 
dissemination, instead of suppression of tumori-
genesis itself (14). Nm23 gene was the fi rst metas-
tasis suppressor genes discovered in 1988, isolated 
from a melanoma cell culture in mice animal mod-
el when it was noticed that cells with a lower nm23 
gene expression have greater metastatic potential 
than those with higher expression. This was later 
confi rmed in other animal and human carcinoma 
models (15, 16). Low expression of nm23 gene is 
associated with more frequent occurrence of me-
tastases in breast, cervical and colorectal carcino-
ma and some other neoplastic lesions (17-20). Re-
searches have also shown that decrease in nm23 
expression can be linked to occurrence of tumor 
metastases in oral squamous cell carcinoma and 
thus can be considered a prognostic factor (15, 21 
- 25). It has also been reported that expression of 
nm23-H1 protein has a role in invasiveness of the 
tumor. OSCC cultures with lowest expression of 
nm23-H1 had invasive morphology, while cells 
with greater expression had noninvasive, multi-
layered morphology (26, 27).
Aim
The most important prognostic factor of oral 
carcinomas is the occurrence of metastases in the 
regional lymph nodes. Thus, new indicators for 
biological behavior of tumors and particularly 
their metastatic potential are being researched 
and defi ned, all for purpose of early diagnosis and 
therapy. Therefore, the aim of this research is to 
defi ne possible prognostic implications of cathep-
sin D and protein nm23 expression upon occur-
rence of regional metastases.
MATERIALS AND METHODS
Research was conducted on the biopsy speci-
mens obtained at the Clinical department of pa-
thology, Clinical hospital Dubrava, Zagreb, Croa-
tia. Biopsy specimens was obtained after clinical 
diagnosis and surgical removal procedure of the 
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primary oral squamous cell carcinoma and re-
gional lymph nodes, in the period between Janu-
ary 1st 2000 and December 31st 2004. Study group 
comprised of 107 patients, 88 men (82.24%), age 
range 34-81 years (men 57.5 years) and 19 women 
(17.76%) aged 37-75 years (mean 55 years). Con-
trol group comprised of 77 specimens of un-
changed oral mucosa of the participants aged 37-
81 (mean 58.5 years), out of which there were 58 
men (75.3%) and 19 women (24.7%).
Each specimen was immunohistochemically 
stained with monoclonal antibodies on cathepsin 
D1 (Novocastra, NCL-CDm) and protein nm23 
(Novocastra, NCL-nm23). Primary antibodies were 
diluted with DAKO REAL antibody dilutent S2022, 
in ration 1:150 for cathepsin D and 1:200 for protein 
nm23. Paraffi  n 5 μm thick sections were deparaf-
fi nazed in xylene and rehydrated in a series of alco-
hol solutions of decreasing alcohol concentration. 
Presentation of antigen was achieved by heating in 
the microwave oven at the maximum temperature 
100°C for 9,5 and 15 min respectively. Cytrate buf-
fer, pH 6 was used. LSAB method (DAKO, LSAB-
system-HRP, K 069 089) and chromogen diamino-
benzidine (DAKO, DAB, K3468) were used for elu-
cidation od the reaction. Mayer›s hematoxylin was 
used for contrast staining.
Gradation of the reactions was defi ned by the 
intensity of the reaction and not the percentage of 
immunoreactive cells. Granulated cytoplasmic re-
action was considered positive for cathepsin D, 
while the positive reaction on protein nm23 was 
diff used cytoplasmic reaction in more than 10% of 
cells. Considering the intensity of cytoplasmic 
staining, reaction could be defi ned as weak (1) 
when the intensity was weaker than the one in the 
positive control, strong (2) when the intensity was 
comparable to the positive control and very strong 
(3) when the intensity was stronger than the posi-
tive control. Positive control for the expression of 
cathepsin D and protein nm23 was positive breast 
carcinoma tissue.
Data were summarized using mean±SD for 
quantitative variables and number and percentage 
for qualitative variables. Comparisons between 
nonparametric quantitative variables were made 
using Mann–Whitney U-test. Multivariate logistic 
regression was performed for the occurrence of 
 regional metastases. All statistical analyses were 
performed with program Statistica for Windows; 
P<0.05 was considered statistically signifi cant.
RESULTS
As seen in the Table 1, diff erences in expres-
sion of both cathepsin D and nm23 between 
healthy epithelium and OSCC were signifi cant 
(cathepsin D, P=0.0002 and nm23, P=0.0000).
Types of immunohystochemical reactions of 
cathepsin D and protein nm23 can be seen in the 
Table 3. Signifi cant diff erence in type of reactions 
between healthy epithelium and OSCC were 
found for both cathepsin D and protein nm23. Ta-
ble 3 shows expression intensity of cathepsin D 
and protein nm23 in tumor stromal tissue. Signifi -
cant diff erence was also found for association of 
expression of nm23 in OSCC cells and diff erentia-
tion of tumor cells (P=0.0129) (Table 4). Expression 
of cathepsin D in tumor stroma in association to 
diff erentiation of tumor cells was found to be sig-
nifi cant (Table 5).
As seen from Table 6, there was signifi cant 
diff erence in expression of nm23 protein and type 
of tumor invasion. Expression of tumor stroma 
can be associated with expression of nm23 protein 
(Table 7).
OSCC with metastases in regional lymph 
nodes have greater and more intense expression 
Table 1.
INTENSITY OF EXPRESSION CATHEPSIN D 
AND nm23 PROTEIN EXPRESSION IN 77 CASES 
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Table 2.
TYPE OF IMMUNOHYSTOCHEMICAL REACTION 
OF CATHEPSIN D AND nm23 PROTEIN IN 77 CASES 



































EXPRESSION INTENSITY OF CATHEPSIN D 
AND nm23 PROTEIN IN TUMOR STROMAL TISSUE
Expression in stromal tissue N %
Cathepsin D No expression 51 47.7
Weak 34 31.8
Strong 21 19.6
Very strong 1 0.9
nm23 No expression 34 31.8
Weak 52 48.6
Strong 21 19.6
Very strong 0 0
of cathepsin D and nm23 protein in tumor stroma 
than OSCC without regional metastases (Table 8).
DISCUSSION
Expression of cathepsin D was noticed in 
only 50% of specimens of the normal epithelium. 
In OSCC, expression of cathepsin D was signifi -
cantly higher and of greater intensity than in nor-
mal epithelium, which is in accordance with the 
available literature (2, 28, 29). Expression of ca-
thepsin D in OSCC was more frequent in the basal 
cell layer, unlike in the normal epithelium in 
which the expression was more common in basal 
and parabasal layer. Similar type of reaction in 
OSCC has been described by Brujan et al., which 
have observed cathepsin D expression in benign 
and malignant breast lesions (30). Expression of 
cathepsin D in stromal tissue has also been de-
scribed as dependent on the hystological type of 
tumor. In this research in 51.4% of all OSCC, ex-
pression of cathepsin D in stromal fi broblasts was 
found and was mostly of lower intensity.
In this research no association between ex-
pression of cathepsin D and protein nm23 in neo-
plastic epithelium and tumor size and types of tu-
mor invasion was found. According to the data 
from the literature, several researches did confi rm a 
correlation between protein nm23 expression and 
sizing of the tumor, being noted that greater ex-
pression was found in tumors of greater size. Thus, 
the expression of nm23 protein is associated with 
tumor proliferation and not only with metastasis 
suppression (15, 17, 18, 27). Expression of cathepsin 
D has not been associated with tumor size (6).
This research has not confi rmed the existence 
of correlation between expression of cathepsin D 
and protein nm 23 in OSCC with tumor diff eren-
tiation. Our results show that there is a signifi cant-
ly greater expression of protein nm23 in poorly 
diff erentiated carcinoma. In the majority of pub-
lished papers, lower expression of protein nm23 
was found in poorly diff erentiated, as well as in 
invasive tumors, even though some researches 
have not found or supported this correlation (11, 
12, 15, 17, 18, 27, 31-36).
Unlike epithelial protein nm23 expression, 
expression of the same protein in stromal fi bro-
blasts proportionally increases with the share of 
stromal connective tissue. Expression of protein 
nm23 and cathepsin D also increased with the tu-
mor size, although this was not signifi cant. Cor-
relation between expression of cathepsin D in tu-
mor stroma and tumor diff erentiation has been 
noticed – in moderately and particularly in poorly 
diff erentiated tumors, the expression of cathepsin 
D was greater and of greater intensity than in well 
diff erentiated tumors.
Infl uence of tumor cells on the stromal cells 
and vice versa has not yet been fully clarifi ed. It is 
known that cathepsin D produced by stromal cells 




EXPRESSION OF CATHEPSIN D AND nm23 IN EPITHELIUM AND TUMOR DIFFERENTIATION 
Expression in the epithelium
Tumor differentiation
Statistical 
signifi cance>75% 25 to 75% <25%
N % N % N %
Cathepsin D No expression 11 50.0 21 34.4 7 29.2
χ2 test=4.568
P=0.3344
Weak expression 8 36.4 20 32.8 11 45.8
Strong expression 2 9.1 20 32.8 5 20.8
Very strong expression 1 4.5 0 0.0 1 4.2
nm23 No expression 2 9.1 3 4,9 3 12,5
χ2test=16.155
P=0.0129
Weak expression 13 59.1 18 29.5 4 16.7
Strong expression 7 31.8 37 60.7 13 54.2
Very strong expression 0 0.0 3 4.9 4 16.7
Total 22 100.0 61 100.0 24 100.0
Table 5. 




signifi cance>75% 25 do 75% <25%
N % N % N %
Cathepsin D No expression 18 81.8 30 49.2 11 45.8
χ2 test=9.613
P=0.0474
Weak expression 3 13.6 21 34.4 11 45.8
Strong and very strong 
expression 1 4.6 10 13.4 2 8.4
nm23 No expression 10 45.5 17 27.9 7 29.2
χ2 test=7.291
P=0.1212
Weak expression 11 50.0 32 52.5 9 37.5
Strong and very strong 
expression 1 4.6 12 19.7 8 33.3
Total 22 100.0 61 100.0 24 100.0
Table 6. 
CATHEPSIN D AND nm23 EXPRESSION AND TYPE OF TUMOR INVASION
Expression in stromal tissue
Type of tumor invasion
Statistical 
signifi canceWide margins Minor foci
With cords and 
and single cells
N % N % N %
Cathepsin D No expression 11 55.0 31 59.6 16 45.7
χ2 test=2.752
P=0.5999
Weak expression 6 30.0 17 32.7 13 37.1
Strong and very strong 
expression 3 15.0 4 7.7 6 17.1
nm23 No expression 4 20.0 24 46.2 6 17.1
χ2test=19.167
P=0.0007
Weak expression 10 50.0 26 50.0 16 45.7
Strong and very strong 
expression 6 30.0 2 3.8 13 37.2
Total 20 100.0 52 100.0 35 100.0
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factor for tumor cells and fi broblasts by auto and 
paracrine signaling. Greater expression of nm23 
gene also induces expression of cathepsin D. So 
far, only scarce data on expression of cathepsin D 
and nm23 gene and particularly their association 
with clinical and pathohystological characteristics 
is available and should defi nitely be investigated 
further (30). Occurrence of regional metastases 
and their association with cathepsin D and nm23 
protein expression in neoplastic epithelium was 
not yet established. However, expression of ca-
thepsin D and protein nm23 in tumor stroma was 
associated with the occurrence of regional metas-
tases. According to our results, OSCC with metas-
tases in regional lymph nodes have greater and 
more intense expression of cathepsin D and pro-
tein nm23 in tumor stroma than OSCC without 
regional metastases. Overview of the literature 
shows diff erent data on association between these 
molecular characteristics and occurrence of re-
gional metastases, even though majority of them 
observed expression in neoplastic epithelium, 
while comparable data on expression in tumor 
stroma are scarce. Expression of cathepsin D in 
stroma of colorectal carcinoma with greater occur-
rence of metastases was described. With regard to 
the expression in tumor cells, greater cathepsin D 
expression and loss of protein nm23 expression in 
neoplastic epithelium was associated with the oc-
currence of regional metastases (6, 10, 15, 17, 18, 
32, 36-40). Some authors could not confi rm these 
fi ndings (31, 33, 41 - 43, 45). 
CONCLUSION
Greater expression of cathepsin D and pro-
tein nm23 in OSCC has been confi rmed in com-
parison to healthy oral epithelium
No correlation between expression of cathep-
sin D and nm23 protein with the size of the tumor 
or tumor invasion was found in OSCC. Correla-
tion between expression of protein nm23 in tumor 
cells and tumor diff erentiation has been found.
Expression of protein nm23 in tumor stroma 
has been associated with the share of connective 
tissue in the tumor stroma. Also, expression of 
nm23 in tumor stroma has been associated with 
the type of tumor invasion, while the stromal ex-
pression of cathepsin D has been associated with 
tumor diff erentiation.
Table 8. 











expression 46 63.0 13 38.2
χ2=5.987
P=0.0501Weak 19 26.0 16 47.1
Strong and 




expression 27 37.0 7 20.6
χ2=6.100
P=0.0474Weak 36 49.3 16 47.0
Strong and 
very strong 10 13.7 11 32.4
Table 7. 
CATHEPSIN D AND nm23 EXPRESSION IN TUMOR STROMA
Expression in tumor stroma
Tumor stroma
Statistical 
signifi cancePoor Moderate Rich
N % N % N %
Cathepsin D No expression 22 68.8 20 50.0 17 48.6
χ2=4.438
P=0.3499
Weak expression 7 21.9 16 40.0 12 34.3
Strong and very strong 
expression 3 9.4 4 10.0 6 17.1
nm23 No expression 20 62.5 10 25.0 4 11.4
χ2=21.821
P=0.0002
Weak expression 9 28.1 22 55.0 21 60.0
Strong and very strong 
expression 3 9.4 8 20.0 10 28.6
Total 32 100.0 40 100.0 35 100.0
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The occurrence of regional metastases has 
not been confi rmed as dependent upon the ex-
pression of cathepsin D and protein nm23 in tu-
mor cells.
Signifi cant molecular characteristics, associ-
ated with the occurrence of regional metastases of 
the OSCC are the expression of cathepsin D and 
protein nm23 in tumor stroma.
Multivariate analysis of all the parameters 
showed that poor stroma of OSCC, in which ca-
thepsin D is not expressed and which invade with 
small cohesive streaks, showed lower risk for the 
occurrence of regional metastases. Moderately-
rich stroma of OSCC with abundant infl ammation 
infi ltrate and greater expression of cathepsin D 
have a slightly greater risk for occurrence of re-
gional metastases.
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